Full Press Release Details
Lexaria Updates Operations
Kelowna, BC / April 7, 2015 / Lexaria, Corp. (OTCQB:LXRP)
(CSE:LXX) (the Company ) provides the following updates.
Lexaria is pleased to announce the manufacturing
of delicious ViPovaTM tea in conventional tea-bags has begun: over
80% of all tea sold in North America is sold within teabags. Simplicity of use
should make it easier for consumers to achieve more consistent portions and
cannabidiol per serving. Lexaria now has the opportunity to offer our tea in
smaller retail packages at lower cost to our customers, offering the potential
of broader consumer acceptance and wider market penetration.
For those who want to try our tea for the first time, but are
reluctant to purchase the existing larger tin for $99, we will for the first
time be able to offer much lower prices for smaller packages. We are currently
awaiting delivery of our new packaging options which will be ready for retail
sale in either April or May. Although the larger tin still offers the best value
per serving, Lexaria expects lower entry-level retail prices to make
ViPovaTM Tea available for enjoyment by everyone.
The new Lexaria website at
lexariaenergy.com is under construction and expected to be operational later
this month. The new site is focused primarily on the food sciences sector in
which we now operate, and will provide more thorough information regarding our
patent-pending infusion technology. The new website will be updated regularly
with important sector-specific information, and the Company will provide
additional information when the new site is ready to launch.
TEA S GOT A NEW FIREND
Lexaria is soon launching a new
print ad campaign featuring the slogan, Tea s Got a new Friend , a
cheeky and fun ad campaign that is sure to provoke conversation. In limited US
circulation to begin, this ad campaign will begin within the next 30 days and is
expected to broaden as the year unfolds.
According to the Tea Association of the USA Inc, Americans
consumed over 79 billion servings of tea in 2012, its popularity far
outstripping any alternative health sector. On any given day, over 150 million
Americans consume tea, and 84% of all tea consumed is black tea. Lexaria is
confident that its unique and proprietary CBD-infusion process will generate
success in this very large market.
Lexaria's shares are quoted in the USA with
symbol LXRP and in Canada with symbol LXX. The company searches for
opportunities that could provide potential above-market returns.
legal CBD oil extracts, grown from legal hemp in locations where it is legal to
do so, in ViPovaTM-branded tea. ViPovaTM uses its
patent-pending process to infuse concentrated amounts of CBD within lipids in
its tea, providing more bioactivity and comfort to the body during the
absorption process. Only ViPovaTM has this ground-breaking technology
for CBD/lipid infusion. www.vipova.com
FOR FURTHER INFORMATION PLEASE CONTACT:
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Current oil and gas production rates may not be sustainable and targeted
production rates may not occur. Factors which could cause actual results to
differ materially from those estimated by the Company include, but are not
limited to, government regulation, managing and maintaining growth, the effect
of adverse publicity, litigation, competition and other factors which may be
identified from time to time in the Company's public announcements and filings.
There is no assurance that the medical marijuana, CBD sector, or alternative
health businesses will provide any benefit to Lexaria, or that the Company will
experience any growth through participation in these sectors. There is no
assurance that existing capital is sufficient for the Company's needs or that it
will need to attempt to raise additional capital. There is no assurance that any
planned corporate activity, business venture, or initiative will be pursued, or
if pursued, will be successful. There is no assurance that any cannabinoid-based
product will promote, assist, or maintain any beneficial human health conditions
whatsoever. No statement herein has been evaluated by the Food and Drug
Administration (FDA). ViPovaTM products are not intended to diagnose,
treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release.